{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:07:10Z","timestamp":1792480030503,"version":"4.5.0"},"reference-count":166,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R35 NS105068-01"],"award-info":[{"award-number":["R35 NS105068-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA211015"],"award-info":[{"award-number":["P50CA211015"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell\u2013engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.<\/jats:p>","DOI":"10.1093\/neuonc\/noaa277","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T01:26:32Z","timestamp":1607736392000},"page":"356-375","source":"Crossref","is-referenced-by-count":87,"title":["Unique challenges for glioblastoma immunotherapy\u2014discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank"],"prefix":"10.1093","volume":"23","author":[{"given":"Pavlina","family":"Chuntova","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, UCSF, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal B","family":"Watchmaker","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, UCSF, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred","family":"Galvez","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B","family":"Heimberger","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W","family":"Newell","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-9501","authenticated-orcid":false,"given":"Aaron","family":"Diaz","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, UCSF, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A","family":"DePinho","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming O","family":"Li","sequence":"additional","affiliation":[{"name":"Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E John","family":"Wherry","sequence":"additional","affiliation":[{"name":"Department of Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Florida College of Medicine, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-0189","authenticated-orcid":false,"given":"Masaki","family":"Terabe","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A","family":"Wainwright","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A","family":"Berzofsky","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Heath","sequence":"additional","affiliation":[{"name":"Institute for Systems Biology, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A","family":"Margolin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Antonio","family":"Chiocca","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, UCSF, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-6640","authenticated-orcid":false,"given":"Benjamin M","family":"Ellingson","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E","family":"Fecci","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Reardon","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Medical Oncology, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M","family":"Liau","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3189-584X","authenticated-orcid":false,"given":"Joseph F","family":"Costello","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, UCSF, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Timmer","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, California"},{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Platten","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany"},{"name":"DKTK CCU Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, UCSF, San Francisco, California"},{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"issue":"1","key":"2021032513211323200_CIT0001","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"7","key":"2021032513211323200_CIT0002","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"10","key":"2021032513211323200_CIT0003","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"2021032513211323200_CIT0004","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with Glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin Cancer Res."},{"key":"2021032513211323200_CIT0005","volume-title":"Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer: Tocagen","year":"2019"},{"key":"2021032513211323200_CIT0006","doi-asserted-by":"crossref","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","article-title":"Immunosuppressive mechanisms in glioblastoma","volume":"17","author":"Nduom","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021032513211323200_CIT0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2020","journal-title":"Nat Med."},{"issue":"11","key":"2021032513211323200_CIT0008","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw144","article-title":"Genomic analysis of immune cell infiltrates across 11 tumor types","volume":"108","author":"Iglesia","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"2021032513211323200_CIT0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021032513211323200_CIT0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"de Groot","year":"2020","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021032513211323200_CIT0011","first-page":"180","article-title":"Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications","volume":"22","author":"Wei","year":"2019","journal-title":"Neuro Oncol."},{"issue":"7706","key":"2021032513211323200_CIT0012","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature."},{"issue":"1","key":"2021032513211323200_CIT0013","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun."},{"issue":"1","key":"2021032513211323200_CIT0014","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol Rev."},{"issue":"10","key":"2021032513211323200_CIT0015","doi-asserted-by":"crossref","first-page":"e1005177","DOI":"10.1371\/journal.ppat.1005177","article-title":"CD39 expression identifies terminally exhausted CD8+ T cells","volume":"11","author":"Gupta","year":"2015","journal-title":"PLoS Pathog."},{"issue":"1","key":"2021032513211323200_CIT0016","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat Commun."},{"issue":"3","key":"2021032513211323200_CIT0017","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41588-019-0558-9","article-title":"The landscape of viral associations in human cancers","volume":"52","author":"Zapatka","year":"2020","journal-title":"Nat Genet."},{"issue":"4","key":"2021032513211323200_CIT0018","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41587-019-0404-8","article-title":"Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy","volume":"38","author":"Millar","year":"2020","journal-title":"Nat Biotechnol."},{"issue":"16","key":"2021032513211323200_CIT0019","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in Glioblastoma: applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2021032513211323200_CIT0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3171\/2019.5.JNS181762","article-title":"The current state of immunotherapy for gliomas: an eye toward the future","volume":"131","author":"Fecci","year":"2019","journal-title":"J Neurosurg."},{"issue":"9","key":"2021032513211323200_CIT0021","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat Med."},{"issue":"8","key":"2021032513211323200_CIT0022","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med."},{"issue":"4","key":"2021032513211323200_CIT0023","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest."},{"issue":"4","key":"2021032513211323200_CIT0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell."},{"issue":"7764","key":"2021032513211323200_CIT0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature."},{"key":"2021032513211323200_CIT0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1479-5876-4-15","article-title":"Innate immune functions of microglia isolated from human glioma patients","volume":"4","author":"Hussain","year":"2006","journal-title":"J Transl Med."},{"issue":"3","key":"2021032513211323200_CIT0027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3171\/jns.1979.50.3.0305","article-title":"Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors","volume":"50","author":"Morantz","year":"1979","journal-title":"J Neurosurg."},{"issue":"4","key":"2021032513211323200_CIT0028","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri.2017.125","article-title":"Microglia and macrophages in brain homeostasis and disease","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Immunol."},{"issue":"2","key":"2021032513211323200_CIT0029","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85841","article-title":"Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype","volume":"1","author":"Gabrusiewicz","year":"2016","journal-title":"JCI Insight."},{"issue":"1","key":"2021032513211323200_CIT0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13059-017-1362-4","article-title":"Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment","volume":"18","author":"M\u00fcller","year":"2017","journal-title":"Genome Biol."},{"issue":"6","key":"2021032513211323200_CIT0031","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.neuron.2018.05.014","article-title":"A combination of ontogeny and CNS environment establishes microglial identity","volume":"98","author":"Bennett","year":"2018","journal-title":"Neuron."},{"key":"2021032513211323200_CIT0032","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","article-title":"The metabolic signature of macrophage responses","volume":"10","author":"Viola","year":"2019","journal-title":"Front Immunol."},{"issue":"10","key":"2021032513211323200_CIT0033","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med."},{"issue":"20","key":"2021032513211323200_CIT0034","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1158\/0008-5472.CAN-07-1243","article-title":"A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients","volume":"67","author":"Hussain","year":"2007","journal-title":"Cancer Res."},{"issue":"19","key":"2021032513211323200_CIT0035","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"2021032513211323200_CIT0036","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","article-title":"COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells","volume":"71","author":"Fujita","year":"2011","journal-title":"Cancer Res."},{"issue":"5","key":"2021032513211323200_CIT0037","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.celrep.2019.06.087","article-title":"Monocytes acquire the ability to prime tissue-resident T cells via IL-10-mediated TGF-beta release","volume":"28","author":"Thompson","year":"2019","journal-title":"Cell Rep."},{"issue":"6","key":"2021032513211323200_CIT0038","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","article-title":"Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma","volume":"35","author":"Chen","year":"2019","journal-title":"Cancer Cell."},{"issue":"3","key":"2021032513211323200_CIT0039","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2159-8290.CD-19-0400","article-title":"Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment","volume":"10","author":"Chen","year":"2020","journal-title":"Cancer Discov."},{"issue":"5","key":"2021032513211323200_CIT0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell."},{"issue":"1","key":"2021032513211323200_CIT0041","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)?","volume":"28","author":"Galea","year":"2007","journal-title":"Trends Immunol."},{"issue":"9","key":"2021032513211323200_CIT0042","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.4049\/jimmunol.164.9.4826","article-title":"Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii","volume":"164","author":"Fischer","year":"2000","journal-title":"J Immunol."},{"issue":"4","key":"2021032513211323200_CIT0043","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.4049\/jimmunol.166.4.2717","article-title":"Brain dendritic cells and macrophages\/microglia in central nervous system inflammation","volume":"166","author":"Fischer","year":"2001","journal-title":"J Immunol."},{"issue":"5","key":"2021032513211323200_CIT0044","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-012-1018-0","article-title":"Brain dendritic cells: biology and pathology","volume":"124","author":"D\u2019Agostino","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2021032513211323200_CIT0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0306-4522(96)00160-1","article-title":"The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system","volume":"74","author":"Matyszak","year":"1996","journal-title":"Neuroscience."},{"issue":"10","key":"2021032513211323200_CIT0046","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/mt.2011.77","article-title":"Combined Flt3L\/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen","volume":"19","author":"King","year":"2011","journal-title":"Mol Ther."},{"issue":"3","key":"2021032513211323200_CIT0047","doi-asserted-by":"crossref","first-page":"e994374","DOI":"10.4161\/2162402X.2014.994374","article-title":"Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas","volume":"4","author":"Flores","year":"2015","journal-title":"Oncoimmunology."},{"issue":"1","key":"2021032513211323200_CIT0048","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1038\/s41467-018-06182-5","article-title":"Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade","volume":"9","author":"Flores","year":"2018","journal-title":"Nat Commun."},{"issue":"42","key":"2021032513211323200_CIT0049","doi-asserted-by":"crossref","first-page":"17872","DOI":"10.1073\/pnas.1010201107","article-title":"Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence","volume":"107","author":"Wakim","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021032513211323200_CIT0050","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3389\/fimmu.2018.01838","article-title":"Tissue-specific roles of NKT cells in tumor immunity","volume":"9","author":"Terabe","year":"2018","journal-title":"Front Immunol."},{"issue":"20","key":"2021032513211323200_CIT0051","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1073\/pnas.1604721113","article-title":"Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity","volume":"113","author":"Yeh","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2021032513211323200_CIT0052","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/07357907.2011.629379","article-title":"Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and paclitaxel","volume":"30","author":"Giussani","year":"2012","journal-title":"Cancer Invest."},{"issue":"12","key":"2021032513211323200_CIT0053","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20051381","article-title":"A nonclassical non-V\u03b114J\u03b118 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance","volume":"202","author":"Terabe","year":"2005","journal-title":"J Exp Med."},{"issue":"9","key":"2021032513211323200_CIT0054","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol."},{"issue":"22","key":"2021032513211323200_CIT0055","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2021032513211323200_CIT0056","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol."},{"key":"2021032513211323200_CIT0057","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fphar.2019.00200","article-title":"The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma","volume":"10","author":"Ladomersky","year":"2019","journal-title":"Front Pharmacol."},{"key":"2021032513211323200_CIT0058","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neulet.2016.08.002","article-title":"Advanced age negatively impacts survival in an experimental brain tumor model","volume":"630","author":"Ladomersky","year":"2016","journal-title":"Neurosci Lett."},{"issue":"7368","key":"2021032513211323200_CIT0059","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature."},{"issue":"8","key":"2021032513211323200_CIT0060","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"2021032513211323200_CIT0061","doi-asserted-by":"crossref","first-page":"e1308616","DOI":"10.1080\/2162402X.2017.1308616","article-title":"Blockade of only TGF-\u03b2 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy","volume":"6","author":"Terabe","year":"2017","journal-title":"Oncoimmunology."},{"issue":"6","key":"2021032513211323200_CIT0062","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/82771","article-title":"NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway","volume":"1","author":"Terabe","year":"2000","journal-title":"Nat Immunol."},{"issue":"21","key":"2021032513211323200_CIT0063","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.1158\/1078-0432.CCR-09-1066","article-title":"Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody","volume":"15","author":"Terabe","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2021032513211323200_CIT0064","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20022227","article-title":"Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence","volume":"198","author":"Terabe","year":"2003","journal-title":"J Exp Med."},{"issue":"5","key":"2021032513211323200_CIT0065","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","article-title":"Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma","volume":"38","author":"Wick","year":"2020","journal-title":"Invest New Drugs."},{"issue":"8","key":"2021032513211323200_CIT0066","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro Oncol."},{"issue":"6230","key":"2021032513211323200_CIT0067","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science."},{"issue":"4","key":"2021032513211323200_CIT0068","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity."},{"issue":"Pt 4","key":"2021032513211323200_CIT0069","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/brain\/aws042","article-title":"Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy","volume":"135","author":"Dutoit","year":"2012","journal-title":"Brain."},{"issue":"2","key":"2021032513211323200_CIT0070","doi-asserted-by":"crossref","first-page":"e1391972","DOI":"10.1080\/2162402X.2017.1391972","article-title":"Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma","volume":"7","author":"Dutoit","year":"2018","journal-title":"Oncoimmunology."},{"issue":"7738","key":"2021032513211323200_CIT0071","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature."},{"issue":"12","key":"2021032513211323200_CIT0072","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1158\/1078-0432.CCR-17-1839","article-title":"Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma","volume":"24","author":"Dettling","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021032513211323200_CIT0073","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00401-017-1702-1","article-title":"Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens","volume":"134","author":"Rapp","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2021032513211323200_CIT0074","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s40478-019-0803-6","article-title":"Immune landscapes associated with different glioblastoma molecular subtypes","volume":"7","author":"Martinez-Lage","year":"2019","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"2021032513211323200_CIT0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med."},{"issue":"4","key":"2021032513211323200_CIT0076","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru","year":"2014","journal-title":"J Med Life."},{"issue":"8","key":"2021032513211323200_CIT0077","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med."},{"issue":"15","key":"2021032513211323200_CIT0078","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","volume":"37","author":"Tawbi","year":"2019","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021032513211323200_CIT0079","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"key":"2021032513211323200_CIT0080","doi-asserted-by":"crossref","first-page":"iii21","DOI":"10.1093\/neuonc\/nox036.071","article-title":"OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143","volume":"19","author":"Reardon","year":"2017","journal-title":"Neuro Oncol."},{"issue":"7","key":"2021032513211323200_CIT0081","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/neuonc\/not031","article-title":"Premetastatic soil and prevention of breast cancer brain metastasis","volume":"15","author":"Liu","year":"2013","journal-title":"Neuro Oncol."},{"issue":"7","key":"2021032513211323200_CIT0082","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell."},{"issue":"7","key":"2021032513211323200_CIT0083","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell."},{"issue":"7","key":"2021032513211323200_CIT0084","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2021032513211323200_CIT0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"Oncologist."},{"issue":"11","key":"2021032513211323200_CIT0086","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med."},{"issue":"11","key":"2021032513211323200_CIT0087","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med."},{"issue":"9","key":"2021032513211323200_CIT0088","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1056\/NEJMc1808251","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med."},{"issue":"19","key":"2021032513211323200_CIT0089","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The promise of neoadjuvant immunotherapy and surgery for cancer treatment","volume":"25","author":"O\u2019Donnell","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2021032513211323200_CIT0090","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"issue":"5","key":"2021032513211323200_CIT0091","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-15-1516","article-title":"Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination","volume":"22","author":"Jackson","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2021032513211323200_CIT0092","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2019","journal-title":"Cancer Cell."},{"issue":"4","key":"2021032513211323200_CIT0093","first-page":"382","article-title":"TLR agonists: are they good adjuvants?","volume":"16","author":"Bhardwaj","year":"2011","journal-title":"Cancer J."},{"issue":"6","key":"2021032513211323200_CIT0094","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"2021032513211323200_CIT0095","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-18-2311","article-title":"Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy","volume":"25","author":"Passaro","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021032513211323200_CIT0096","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/noy170","article-title":"Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?","volume":"21","author":"Chiocca","year":"2019","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021032513211323200_CIT0097","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1038\/s41598-020-61736-2","article-title":"Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses","volume":"10","author":"Alayo","year":"2020","journal-title":"Sci Rep."},{"issue":"1","key":"2021032513211323200_CIT0098","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Mol Ther."},{"issue":"7","key":"2021032513211323200_CIT0099","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/neuonc\/nox038","article-title":"Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity","volume":"19","author":"Hiraoka","year":"2017","journal-title":"Neuro Oncol."},{"issue":"7","key":"2021032513211323200_CIT0100","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/neuonc\/nox037","article-title":"Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model","volume":"19","author":"Mitchell","year":"2017","journal-title":"Neuro Oncol."},{"issue":"suppl_6","key":"2021032513211323200_CIT0101","doi-asserted-by":"crossref","first-page":"vi6","DOI":"10.1093\/neuonc\/noy148.021","article-title":"Immunologic trends associated with patient outcomes in a phase 1 clinical trial of Toca 511 and Toca FC in recurrent high grade glioma","volume":"20","author":"Accomando","year":"2018","journal-title":"Neuro Oncol."},{"issue":"341","key":"2021032513211323200_CIT0102","doi-asserted-by":"crossref","first-page":"341ra375","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci Transl Med."},{"issue":"10","key":"2021032513211323200_CIT0103","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol."},{"issue":"12","key":"2021032513211323200_CIT0104","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first Phase I\/IIa glioblastoma trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol Ther."},{"issue":"2","key":"2021032513211323200_CIT0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med."},{"issue":"14","key":"2021032513211323200_CIT0106","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021032513211323200_CIT0107","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djy033","article-title":"Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy","volume":"110","author":"Kurokawa","year":"2018","journal-title":"J Natl Cancer Inst."},{"issue":"7738","key":"2021032513211323200_CIT0108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature."},{"issue":"12","key":"2021032513211323200_CIT0109","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1172\/JCI140378","article-title":"Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma","volume":"130","author":"Mueller","year":"2020","journal-title":"J Clin Invest."},{"issue":"3","key":"2021032513211323200_CIT0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2021032513211323200_CIT0111","doi-asserted-by":"crossref","first-page":"350748","DOI":"10.1155\/2010\/350748","article-title":"Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection","volume":"2010","author":"Geletneky","year":"2010","journal-title":"J Biomed Biotechnol."},{"issue":"23","key":"2021032513211323200_CIT0112","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1158\/1078-0432.CCR-07-1306","article-title":"Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021032513211323200_CIT0113","doi-asserted-by":"crossref","first-page":"11470","DOI":"10.1038\/s41598-018-29929-y","article-title":"Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo","volume":"8","author":"Bai","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"2021032513211323200_CIT0114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol Ther."},{"issue":"1","key":"2021032513211323200_CIT0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2021032513211323200_CIT0116","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat Med."},{"issue":"26","key":"2021032513211323200_CIT0117","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med."},{"issue":"399","key":"2021032513211323200_CIT0118","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med."},{"issue":"6","key":"2021032513211323200_CIT0119","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell."},{"key":"2021032513211323200_CIT0120","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids."},{"issue":"4","key":"2021032513211323200_CIT0121","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.cell.2019.10.002","article-title":"Attacking latent HIV with convertibleCAR-T Cells, a highly adaptable killing platform","volume":"179","author":"Herzig","year":"2019","journal-title":"Cell."},{"issue":"6","key":"2021032513211323200_CIT0122","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"issue":"1","key":"2021032513211323200_CIT0123","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun."},{"issue":"13","key":"2021032513211323200_CIT0124","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1158\/0008-5472.CAN-06-3280","article-title":"Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors","volume":"67","author":"Sasaki","year":"2007","journal-title":"Cancer Res."},{"key":"2021032513211323200_CIT0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-5-10","article-title":"Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models","volume":"5","author":"Zhu","year":"2007","journal-title":"J Transl Med."},{"issue":"2","key":"2021032513211323200_CIT0126","doi-asserted-by":"crossref","first-page":"e988098","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology."},{"issue":"7693","key":"2021032513211323200_CIT0127","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature."},{"issue":"7693","key":"2021032513211323200_CIT0128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature."},{"issue":"4","key":"2021032513211323200_CIT0129","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41596-020-0294-8","article-title":"Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands","volume":"15","author":"Chang","year":"2020","journal-title":"Nat Protoc."},{"issue":"2","key":"2021032513211323200_CIT0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/btm2.10097","article-title":"TGF-\u03b2-responsive CAR-T cells promote anti-tumor immune function","volume":"3","author":"Hou","year":"2018","journal-title":"Bioeng Transl Med."},{"issue":"1","key":"2021032513211323200_CIT0131","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun."},{"issue":"3","key":"2021032513211323200_CIT0132","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","article-title":"Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape","volume":"134","author":"Ellingson","year":"2017","journal-title":"J Neurooncol."},{"issue":"1","key":"2021032513211323200_CIT0133","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12885-018-4131-1","article-title":"Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases","volume":"18","author":"Ranjan","year":"2018","journal-title":"BMC Cancer."},{"issue":"2","key":"2021032513211323200_CIT0134","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"15","key":"2021032513211323200_CIT0135","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"2021032513211323200_CIT0136","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3171\/jns.2005.103.3.0428","article-title":"Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury","volume":"103","author":"Smith","year":"2005","journal-title":"J Neurosurg."},{"issue":"5","key":"2021032513211323200_CIT0137","doi-asserted-by":"crossref","first-page":"e19662","DOI":"10.1371\/journal.pone.0019662","article-title":"Monitoring of in vivo function of superparamagnetic iron oxide labelled murine dendritic cells during anti-tumour vaccination","volume":"6","author":"Tavar\u00e9","year":"2011","journal-title":"PLoS One."},{"issue":"5","key":"2021032513211323200_CIT0138","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ijc.22385","article-title":"Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines","volume":"120","author":"Verdijk","year":"2007","journal-title":"Int J Cancer."},{"issue":"3","key":"2021032513211323200_CIT0139","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CJI.0b013e318197b2a0","article-title":"Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI","volume":"32","author":"Dekaban","year":"2009","journal-title":"J Immunother."},{"issue":"6","key":"2021032513211323200_CIT0140","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol."},{"key":"2021032513211323200_CIT0141","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-016-0162-9","article-title":"Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade","volume":"4","author":"Tsai","year":"2016","journal-title":"J Immunother Cancer."},{"issue":"12","key":"2021032513211323200_CIT0142","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med."},{"issue":"4","key":"2021032513211323200_CIT0143","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.119.229781","article-title":"First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting","volume":"61","author":"Pandit-Taskar","year":"2020","journal-title":"J Nucl Med."},{"issue":"2","key":"2021032513211323200_CIT0144","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clineuro.2012.11.002","article-title":"Potential of MR spectroscopy for assessment of glioma grading","volume":"115","author":"Bulik","year":"2013","journal-title":"Clin Neurol Neurosurg."},{"issue":"11","key":"2021032513211323200_CIT0145","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/neuonc\/nov106","article-title":"pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI","volume":"17","author":"Harris","year":"2015","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021032513211323200_CIT0146","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11060-019-03132-z","article-title":"pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma","volume":"142","author":"Yao","year":"2019","journal-title":"J Neurooncol."},{"issue":"9","key":"2021032513211323200_CIT0147","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/neuonc\/now058","article-title":"Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas","volume":"18","author":"Albert","year":"2016","journal-title":"Neuro Oncol."},{"key":"2021032513211323200_CIT0148","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nicl.2016.12.020","article-title":"The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy","volume":"13","author":"Galldiks","year":"2017","journal-title":"Neuroimage Clin."},{"issue":"1","key":"2021032513211323200_CIT0149","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun."},{"issue":"4","key":"2021032513211323200_CIT0150","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2967\/jnumed.116.177659","article-title":"Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging","volume":"58","author":"Mayer","year":"2017","journal-title":"J Nucl Med."},{"issue":"1","key":"2021032513211323200_CIT0151","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.crad.2019.07.001","article-title":"Machine learning and glioma imaging biomarkers","volume":"75","author":"Booth","year":"2020","journal-title":"Clin Radiol."},{"key":"2021032513211323200_CIT0152","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fonc.2019.00374","article-title":"Radiomics in glioblastoma: current status and challenges facing clinical implementation","volume":"9","author":"Chaddad","year":"2019","journal-title":"Front Oncol."},{"issue":"1","key":"2021032513211323200_CIT0153","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1038\/s41467-019-11007-0","article-title":"Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma","volume":"10","author":"Elshafeey","year":"2019","journal-title":"Nat Commun."},{"issue":"12","key":"2021032513211323200_CIT0154","doi-asserted-by":"crossref","first-page":"e1501137","DOI":"10.1080\/2162402X.2018.1501137","article-title":"Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models","volume":"7","author":"Genoud","year":"2018","journal-title":"Oncoimmunology."},{"issue":"8","key":"2021032513211323200_CIT0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00262-014-1561-8","article-title":"Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells","volume":"63","author":"Kosaka","year":"2014","journal-title":"Cancer Immunol Immunother."},{"issue":"7514","key":"2021032513211323200_CIT0156","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature."},{"key":"2021032513211323200_CIT0157","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3389\/fonc.2018.00656","article-title":"Harnessing radiation biology to augment immunotherapy for glioblastoma","volume":"8","author":"Rajani","year":"2018","journal-title":"Front Oncol."},{"key":"2021032513211323200_CIT0158","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-3-26","article-title":"Design, analysis and presentation of factorial randomised controlled trials","volume":"3","author":"Montgomery","year":"2003","journal-title":"BMC Med Res Methodol."},{"issue":"16","key":"2021032513211323200_CIT0159","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1200\/JCO.2002.03.003","article-title":"Factorial design considerations","volume":"20","author":"Green","year":"2002","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021032513211323200_CIT0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/neuonc\/nou314","article-title":"Factorial clinical trials: a new approach to phase II neuro-oncology studies","volume":"17","author":"Iwamoto","year":"2015","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021032513211323200_CIT0161","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/neuonc\/nou155","article-title":"Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and\/or thalidomide for glioblastoma","volume":"17","author":"Penas-Prado","year":"2015","journal-title":"Neuro Oncol."},{"issue":"7","key":"2021032513211323200_CIT0162","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/neuonc\/noy020","article-title":"Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium","volume":"20","author":"GLASS Consortium","year":"2018","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021032513211323200_CIT0163","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res."},{"key":"2021032513211323200_CIT0164","doi-asserted-by":"crossref","first-page":"TPS2079","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2079","article-title":"Individualized screening trial of innovative glioblastoma therapy (INSIGhT)","volume":"35","author":"Alexander","year":"2017","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021032513211323200_CIT0165","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/neuonc\/nox216","article-title":"Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study","volume":"20","author":"Pfaff","year":"2018","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021032513211323200_CIT0166","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/noy161","article-title":"N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma","volume":"21","author":"Wick","year":"2019","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa277\/36218499\/noaa277.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/3\/356\/36722894\/noaa277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/3\/356\/36722894\/noaa277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T09:29:47Z","timestamp":1616664587000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/3\/356\/6047273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":166,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,24]]},"published-print":{"date-parts":[[2021,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa277","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,12,24]]}}}